The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexFemale
Age46-60
SponsorMayo Clinic
About this trial
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
Eligibility criteria
Qualifiers
Females
Age 46-60 years old.
BMI ≥30 kg/m2 or BMI ≥27 kg/m2 in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
Presence of bothersome hot flashes (an average of ≥ 28 episodes during a consecutive 2-week period with symptom severity sufficient to have prompted the participant to seek therapeutic treatment).
Disqualifiers
Current or recent use (past 4 weeks) treatment with menopausal hormone therapy.
Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).
Vaginal estrogen.
Androgens.
Trial design
Treatments tested in this trial
- Tirzepatide
- Placebo
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov